Deutsche Bank AG Purchases 14,929 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Deutsche Bank AG grew its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 51.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,809 shares of the company’s stock after acquiring an additional 14,929 shares during the period. Deutsche Bank AG owned about 0.09% of Prestige Consumer Healthcare worth $3,421,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Franklin Resources Inc. lifted its stake in shares of Prestige Consumer Healthcare by 0.7% during the 4th quarter. Franklin Resources Inc. now owns 21,735 shares of the company’s stock worth $1,697,000 after buying an additional 150 shares during the last quarter. CIBC Private Wealth Group LLC lifted its stake in shares of Prestige Consumer Healthcare by 48.9% during the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock worth $34,000 after buying an additional 152 shares during the last quarter. QRG Capital Management Inc. lifted its stake in shares of Prestige Consumer Healthcare by 3.3% during the 4th quarter. QRG Capital Management Inc. now owns 5,496 shares of the company’s stock worth $429,000 after buying an additional 176 shares during the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of Prestige Consumer Healthcare by 3.0% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 7,026 shares of the company’s stock worth $549,000 after buying an additional 207 shares during the last quarter. Finally, Summit Investment Advisors Inc. lifted its stake in shares of Prestige Consumer Healthcare by 4.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,182 shares of the company’s stock worth $405,000 after buying an additional 211 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PBH shares. Royal Bank of Canada upgraded shares of Prestige Consumer Healthcare to a “hold” rating in a research note on Thursday, May 8th. Canaccord Genuity Group raised their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Oppenheimer raised their target price on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. DA Davidson raised their target price on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Finally, StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $93.33.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock opened at $87.55 on Wednesday. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The company has a 50-day simple moving average of $83.46 and a two-hundred day simple moving average of $82.08. The stock has a market capitalization of $4.33 billion, a price-to-earnings ratio of 20.50, a price-to-earnings-growth ratio of 2.69 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, May 8th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. The firm had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same period last year, the firm earned $1.02 EPS. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. The trade was a 8.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.